Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 3428253, 13 pages
https://doi.org/10.1155/2017/3428253
Review Article

Add-On Therapy with Traditional Chinese Medicine Improves Outcomes and Reduces Adverse Events in Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials

1Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China
2Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
3Department of Traditional Chinese Medicine, Medical College of Xiamen University, Xiamen 361005, China

Correspondence should be addressed to Xiaorong Chen; moc.361@nehc3gnoroaix and Yongchun Yu; moc.361@88nuhcgnoyeuy

Received 31 January 2017; Accepted 4 April 2017; Published 7 June 2017

Academic Editor: Senthami R. Selvan

Copyright © 2017 Zongguo Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma,” Journal of Hepatology, vol. 56, no. 4, pp. 908–943, 2012. View at Google Scholar
  2. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Allemani, H. K. Weir, H. Carreira et al., “Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2),” The Lancet, vol. 385, no. 9972, pp. 977–1010, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Lam, Z. Jiang, F. Guan et al., “PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment,” Scientific Reports, vol. 5, article 9384, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. H. B. El-Serag, “Hepatocellular carcinoma,” New England Journal of Medicine, vol. 365, no. 12, pp. 1118–1127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Li, G. Yang, X. Li et al., “Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese,” PLoS ONE, vol. 8, no. 4, Article ID e60338, 2013. View at Google Scholar
  7. A. R. M. R. Amin, O. Kucuk, F. R. Khuri, and D. M. Shin, “Perspectives for cancer prevention with natural compounds,” Journal of Clinical Oncology, vol. 27, no. 16, pp. 2712–2725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Guan and Z. Fang, “Advances in TCM treatment of primary hepatocarcinoma,” Journal of Traditional Chinese Medicine, vol. 20, no. 3, pp. 223–226, 2000. View at Google Scholar · View at Scopus
  9. M.-B. Meng, Y.-L. Cui, Y.-S. Guan et al., “Traditional Chinese medicine plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma,” Journal of Alternative and Complementary Medicine, vol. 14, no. 8, pp. 1027–1042, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. M.-B. Meng, Q.-L. Wen, Y.-L. Cui, B. She, and R.-M. Zhang, “Meta-analysis: Traditional Chinese medicine for improving immune response in patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization,” Explore, vol. 7, no. 1, pp. 37–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Liu, “A clinical analysis of strengthening integrated traditional Chinese and Western medicine therapy for prevention and treatment of liver cancer,” Journal of Clinical Hepatology, vol. 32, no. 4, pp. 615–617, 2015 (Chinese). View at Google Scholar
  12. Y. Zhang, R.-M. Zhang, and J. Chang, “Quality assessment of the report of randomized controlled trials on treatment of liver carcinoma with traditional Chinese medicine,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 28, no. 7, pp. 588–590, 2008 (Chinese). View at Google Scholar · View at Scopus
  13. P. Wu, J. J. Dugoua, O. Eyawo, and E. J. Mills, “Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis,” Journal of Experimental and Clinical Cancer Research, vol. 28, no. 1, article 112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. T. Higgins and S. Green, Eds., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, (Updated March 2011), The Cochrane Collaboration, 2011.
  15. A. B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler, “Reporting results of cancer treatment,” Cancer, vol. 47, no. 1, pp. 207–214, 1981. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Bogaerts, R. Ford, D. Sargent et al., “Individual patient data analysis to assess modifications to the RECIST criteria,” European Journal of Cancer, vol. 45, no. 2, pp. 248–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. W. Yates, B. Chalmer, and F. P. McKegney, “Evaluation of patients with advanced cancer using the Karnofsky performance status,” Cancer, vol. 45, no. 8, pp. 2220–2224, 1980. View at Publisher · View at Google Scholar · View at Scopus
  19. J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta-analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. F. Huang, H. Z. Li, Z. J. Zhang et al., “Clinical study on Jianpi Xiaoji oral liquid for improvement of life quality in 32 cases of late liver cancer,” Zhong Yi Za Zhi, vol. 45, no. 10, pp. 754–756, 2001 (Chinese). View at Google Scholar
  21. X. Q. Huang, H. Q. Tian, G. W. Liang, X. Z. Chen, and Q. P. Shen, “Study of combined treatment with traditional Chinese medicine for advanced primary hepatocarcinoma,” Chinese Journal of Clinical Oncology and Rehabilitation, vol. 16, no. 1, pp. 57–60, 2009 (Chinese). View at Google Scholar
  22. Q. Li, B. M. Sun, Y. H. Peng, Z. Z. Fan, and J. Sun, “Clinical study on the treatment of primary liver cancer by cinobufotain combined with transcatheter arterial chemoembolization,” Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai, vol. 22, no. 2, pp. 32–34, 2008 (Chinese). View at Google Scholar
  23. J. C. Li, D. Y. Fan, P. Z. Liu, Y. C. Luo, W. K. Gao, and H. J. Liang, “Integrative medicine therapy for 32 cases hepatocellular carcinoma with advanced stage,” Zhong Yi Yan Jiu, vol. 26, no. 1, pp. 21–23, 2013 (Chinese). View at Google Scholar
  24. Y. Y. Li, L. X. Zhou, R. J. Ren, and Y. L. Liu, “Clinical observation of traditional Chinese medicine therapy for hepatocellular carcinoma with late stage,” Chinese Journal of Modern Drug Application, vol. 10, no. 6, pp. 243-244, 2016 (Chinese). View at Google Scholar
  25. L.-Z. Lin, D.-H. Zhou, K. Liu, F.-J. Wang, S.-Q. Lan, and X.-W. Ye, “Analysis on the prognostic factors in patients with large hepatocarcinoma treated by shentao ruangan pill and hydroxycamptothecine,” Zhongguo Zhong Xi Yi Jie He Za Zhi, vol. 25, no. 1, pp. 8–11, 2005 (Chinese). View at Google Scholar · View at Scopus
  26. C. Q. Ling, Z. Chen, D. Z. Zhu et al., “Integrative medicine therapy for 313 cases hepatocellular carcinoma,” Shijie Hua Ren Xiao Hua Za Zhi, vol. 9, no. 1, pp. 114-115, 2001 (Chinese). View at Google Scholar
  27. Y. M. Liu, “Self-designed Gan'ai decotion improves quality of life in 32 cases of hepatocellular carcinoma with advanced stage,” Guang Ming Zhong Yi, vol. 26, no. 9, pp. 1822-1823, 2011 (Chinese). View at Google Scholar
  28. H. Liu and W. Z. Lü, “Application value of traditional Chinese and western medicine in the treatment of postoperative recurrence of liver cancer,” The Practical Journal of Cancer, vol. 31, no. 3, pp. 493–495, 2016 (Chinese). View at Google Scholar
  29. X. C. Lu, “Clinical study on treatmeant of primary liver cancer with portal vein tumor thrombus by compositive integrated traditional chinese and clinical medicine,” China Journal of Modern Medicine, vol. 18, no. 21, pp. 3163–3167, 2008 (Chinese). View at Google Scholar
  30. C. Lü X, P. Zhao, L. Y. Li, J. L. Liu, and Z. S. Xia, “Clinical study on intermediate or advanced primary liver cancer by connective and compositive treatment of traditional Chinese and western medicine,” China Journal of Modern Medicine, vol. 24, no. 36, pp. 61–66, 2014 (Chinese). View at Google Scholar
  31. L. Min and R. Y. Zhou, “Impact of Enforcing spleen and nourishing kidney herbs on thyroid hormones and clinical efficacy of hepatocellular carcinoma patients after hepatectomy,” Zhong Yi Za Zhi, vol. 52, supplement, pp. 96–98, 2011 (Chinese). View at Google Scholar
  32. H. P. Ren and L. Cheng, “Clinical observation of nourishing spleen and dredging Qi herbs combined with transcatheter arterial chemoembolization therapy for middle-advanced stage hepatocellular carcinoma,” Zhong Xi Yi Jie He Za Zhi, vol. 24, no. 9, pp. 838–840, 2004 (Chinese). View at Google Scholar
  33. Z. X. Shao, Z. G. Cheng, X. E. Yi et al., “Clinical study on treatment of middle-advanced stage liver cancer by combined treatment of hepatic artery chemoembolization with Gan'ai no. I and no. II,” Zhong Xi Yi Jie He Za Zhi, vol. 21, no. 3, pp. 168–170, 2001 (Chinese). View at Google Scholar · View at Scopus
  34. D. B. Shi and T. T. Tang, “Clinical observation of palliative therapy with traditional Chinese medicine for middle-advanced stage hepatocellular carcinoma,” Liaoning Zhong Yi Za Zhi, vol. 40, no. 9, pp. 1855-1856, 2013 (Chinese). View at Google Scholar
  35. H. Q. Tian, G. W. Liang, X. Q. Huang et al., “Prospective randomized controlled study on complex treatment of traditional Chinese medicine to advanced primary hepatocarcinoma,” China Medical Herald, vol. 5, no. 31, pp. 17–20, 2008 (Chinese). View at Google Scholar
  36. Y. X. Xie, S. H. Wang, J. Q. Yang et al., “Yao medicine Quanti Tang combined with TACE in treating primary liver cancer randomized parallel controlled study,” Journal of Practical Traditional Chinese Internal Medicine, vol. 29, no. 4, pp. 74–76, 2014 (Chinese). View at Google Scholar
  37. Z. J. Yang, C. M. Deng, J. B. Liu, and C. J. Huang, “Influence on the life quality and immune function of liver cancer patients treated with Chinese medicine combined with western medicine,” China Journal of Chinese Medicine, vol. 26, no. 8, pp. 907–909, 2011 (Chinese). View at Google Scholar
  38. J.-Z. Yi, Y.-C. Xie, and X.-H. Deng, “Clinical observation on the effect of Kang'ai injection combined with transcatheter arterial chemoembolization on hepatocellular carcinoma in 36 patients,” Tumor, vol. 28, no. 11, pp. 997–1000, 2008 (Chinese). View at Publisher · View at Google Scholar · View at Scopus
  39. C. Zhong, H.-D. Li, D.-Y. Liu et al., “Clinical study of hepatectomy combined with Jianpi Huayu therapy for hepatocellular carcinoma,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 14, pp. 5951–5957, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Pircher, M. Medinger, and J. Drevs, “Liver cancer: targeted future options,” World Journal of Hepatology, vol. 3, no. 2, pp. 38–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Wu, P. Lu, L. Shi, and S. Li, “Traditional Chinese patent medicines for cancer treatment in China: a nationwide medical insurance data analysis,” Oncotarget, vol. 6, no. 35, pp. 38283–38295, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. M.-C. Wu, “Traditional Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems,” Zhong Xi Yi Jie He Xue Bao, vol. 1, no. 3, pp. 163-164, 2003 (Chinese). View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Hu, S. Wang, X. Wu et al., “Chinese herbal medicine-derived compounds for cancer therapy: a focus on hepatocellular carcinoma,” Journal of Ethnopharmacology, vol. 149, no. 3, pp. 601–612, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. C.-Q. Ling, X.-Q. Yue, and C. Ling, “Three advantages of using traditional Chinese medicine to prevent and treat tumor,” Journal of Integrative Medicine, vol. 12, no. 4, pp. 331–335, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. V. B. Konkimalla and T. Efferth, “Evidence-based Chinese medicine for cancer therapy,” Journal of Ethnopharmacology, vol. 116, no. 2, pp. 207–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. C.-Q. Ling, L.-N. Wang, Y. Wang et al., “The roles of traditional Chinese medicine in gene therapy,” Journal of Integrative Medicine, vol. 12, no. 2, pp. 67–75, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. Y.-H. Liao, C.-C. Lin, H.-C. Lai, J.-H. Chiang, J.-G. Lin, and T.-C. Li, “Adjunctive traditional Chinese medicine therapy improves survival of liver cancer patients,” Liver International, vol. 35, no. 12, pp. 2595–2602, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. S. S. Hwang, C. B. Scott, V. T. Chang, J. Cogswell, S. Srinivas, and B. Kasimis, “Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress,” Cancer Investigation, vol. 22, no. 5, pp. 678–687, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. P. D. Evers, J. E. Logan, V. Sills, and A. I. Chin, “Karnofsky Performance Status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma,” World Journal of Urology, vol. 32, no. 2, pp. 385–391, 2014. View at Publisher · View at Google Scholar · View at Scopus
  50. C. E. DeSantis, C. C. Lin, A. B. Mariotto et al., “Cancer treatment and survivorship statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 4, pp. 252–271, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Akin, G. Can, A. Aydiner, K. Ozdilli, and Z. Durna, “Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy,” European Journal of Oncology Nursing, vol. 14, no. 5, pp. 400–409, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ohnishi and H. Takeda, “Herbal medicines for the treatment of cancer chemotherapy-induced side effects,” Frontiers in Pharmacology, vol. 6, article 14, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. W. Tao, X. Luo, B. Cui et al., “Practice of traditional Chinese medicine for psycho-behavioral intervention improves quality of life in cancer patients: a systematic review and meta-analysis,” Oncotarget, vol. 6, no. 37, pp. 39725–39739, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. E. J. Ladas and K. M. Kelly, “Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer?” Journal of Alternative and Complementary Medicine, vol. 9, no. 3, pp. 411–416, 2003. View at Publisher · View at Google Scholar · View at Scopus